IVD
For in vitro diagnostic use.
Elecsys® CK-MB STAT
USA ONLY:Creatine kinase (CK) is a dimeric enzyme which occurs in four different forms: a mitochondrial isoenzyme and the cytosolic isoenzymes CK‑MM (muscle type), CK‑BB (brain type) and CK‑MB.1,2The determination of CK‑MB mass in serum is an important element in the diagnosis of myocardial ischemia, e.g. in acute myocardial infarction, myocarditis, etc.1,2 CK‑MB is detectable in the blood about 3‑8 hours after the onset of cardiac symptoms and can remain detectable over a lengthy period of time, depending on the course of the condition.1Elevated CK‑MB is not specific for MI (myocardial infarction) and may be detected in other disease states.3 Elevated CK‑MB values should be interpreted in conjunction with clinical presentation and medical history.The sensitivity of a CK‑MB determination is dependent upon the time at which a sample was taken. Follow‑up assays are therefore meaningful.1,4The Elecsys CK‑MB STAT assay employs two different monoclonal antibodies directed against human CK‑MB.1 Rozenman Y, Gotsman MS. The earliest diagnosis of acute myocardial infarction. Annu Rev Med 1994;45:31-44.2 Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: Is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-763.3 Ay H, Arsava EM, Saribas O. Creatine Kinase-MB Elevation After Stroke is not cardiac in origin. Stroke 2002;(33)286-289.4 Apple FS. Diagnostic markers for detection of acute myocardial infarction and reperfusion. Laboratory Medicine 1992;23(5):297-322.GLOBAL:Creatine kinase (CK) is a dimeric enzyme which occurs in four different forms: a mitochondrial isoenzyme and the cytosolic isoenzymes CK‑MM (muscle type), CK‑BB (brain type) and CK‑MB.1,2The determination of CK‑MB mass in serum is an important element in the diagnosis of myocardial ischemia, e.g. in acute myocardial infarction, myocarditis, etc.1,2 CK‑MB is detectable in the blood about 3‑8 hours after the onset of cardiac symptoms and can remain detectable over a lengthy period of time, depending on the course of the condition.1CK‑MB may also appear in other clinical conditions, e.g. in rhabdomyolysis and stroke.1,4 Within the scope of laboratory diagnostics, the determination of total CK, troponin T and/or myoglobin can contribute to the differentiation of these clinical pictures. Because of their higher sensitivity and specificity, cardiac troponins, measured by high-sensitivity assays, are the preferred biomarkers to define myocardial infarction,3 and if a troponin assay is not available, the best alternative is CK-MB measured by a mass assay.3The sensitivity of a CK‑MB determination is dependent upon the time at which a sample was taken. Follow-up assays are therefore meaningful.1,5The Elecsys CK‑MB assay employs two different monoclonal antibodies directed against human CK‑MB.1 Rozenman Y, Gotsman MS. The earliest diagnosis of acute myocardial infarction. Annu Rev Med 1994;45:31-44.2 Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: Is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-763.3 Thygesen K, Alpert JS, Jaffe AS, et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infaction. Fourth Universal Definition of Myocardial Infarction. Glob Heart 2018;13(4):305-338.4 Ay H, Arsava EM, Saribas O. Creatine Kinase-MB Elevation After Stroke is not cardiac in origin. Stroke 2002;(33)286-289. 5 Apple FS. Diagnostic markers for detection of acute myocardial infarction and reperfusion. Laboratory Medicine 1992;23(5):297-322.
